For example, individuals with the CYP2C19 poor metabolizer genotype have been shown to have a higher risk of cardiovascular disease, regardless of the antiplatelet clopidogrel bioactivation [14,26]. This evidence concerns the gene CYP2C19 and cardiovascular disorder.